GLP-1 compounds such as semaglutide and tirzepatide get most of the attention, and for good reason: their human trials are the strongest in the field. But they work mainly by turning appetite down. A second group of compounds works on a different idea altogether, nudging how the body burns and stores energy rather than how hungry you feel. Here is what each one is, what the research actually shows, and why people pair them with a GLP-1 rather than use them instead of one.
Fat-loss peptides beyond GLP-1s in 60 seconds
- AOD-9604 is a fragment of human growth hormone, designed to keep its fat-burning signal without its effect on growth.
- 5-Amino-1MQ blocks an enzyme called NNMT that fat cells use to store energy. It is a small molecule, not a peptide.
- SLU-PP-332 switches on the same energy-burning programme in muscle that endurance exercise does. Also a small molecule.
- MOTS-c is a peptide made by your own mitochondria that helps cells use glucose and fat for fuel.
- None of the four has human weight-loss results to match the GLP-1s. Their appeal is that they work on energy use, not appetite.


AOD-9604
AOD-9604 is a modified piece of the tail end of human growth hormone, the part linked to breaking down fat. The idea was to keep that fat-mobilising signal while leaving out growth hormone’s effects on growth and blood sugar. In obese mice it increased fat breakdown and reduced fat gain without raising IGF-1.
The honest part: a larger human trial run in the 2000s did not show meaningful weight loss over placebo, and development as an obesity drug stopped there. It was well tolerated in those studies, which is part of why it has stayed popular in research circles, often as a pairing for fat loss alongside a GLP-1 rather than on its own. It also appears in two of our blends: Lean Dreams with DSIP, and Shredded with tesamorelin and MOTS-c.
5-Amino-1MQ
5-Amino-1MQ inhibits nicotinamide N-methyltransferase, NNMT for short. NNMT is very active in fat tissue, and it uses up some of the raw material cells need to make NAD+, the molecule at the centre of cellular energy. Block NNMT and, in theory, fat cells burn more and store less.
In mice on a high-fat diet, an NNMT inhibitor from this family reduced body weight and fat mass and shrank fat cells without the animals eating less. That is the attraction: a lever that does not depend on appetite. There are no published human weight-loss trials yet. It is also one of the three ingredients in our Limitless pen, alongside NAD+ and MOTS-c, which approaches cellular energy from three angles at once.
SLU-PP-332
SLU-PP-332 activates a family of receptors called ERRs, oestrogen-related receptors. Despite the name, they have nothing to do with oestrogen. They control the genes muscle switches on when you train for endurance: more mitochondria, more fat burned for fuel, more stamina. That is why it is often described as an exercise mimetic.
In mice it increased running endurance and, in obese animals, reduced fat mass and improved insulin sensitivity. Like 5-Amino-1MQ, it has no human trials yet. People who research it are usually interested in exactly that endurance and fat-oxidation effect, and it is often discussed together with MOTS-c because the two act on overlapping energy pathways.
MOTS-c
MOTS-c is a short peptide encoded in the DNA of your mitochondria rather than the cell nucleus, which made its discovery in 2015 a genuine surprise. It moves to the nucleus under stress and helps switch on genes involved in using glucose and fat. In mice it prevented weight gain on a high-fat diet, improved insulin sensitivity and, in older animals, improved physical capacity.
Human data is early. Levels of MOTS-c rise with exercise, and an analogue has been through small early-stage human trials, but there are no large weight-loss studies. We stock it as Mito Boost (60mg pen) and as a Noventra 10mg pen.
GLP-1 compounds
- Mainly turn appetite down
- The strongest human trials in the field
- Semaglutide, tirzepatide, retatrutide
AOD-9604, 5-Amino-1MQ, SLU-PP-332, MOTS-c
- Work on how energy is burned and stored
- No human weight-loss results to match the GLP-1s
- Often paired with a GLP-1 rather than used instead
Why people pair these with a GLP-1
The pattern we see most is simple. A GLP-1 does the heavy lifting on appetite and weight. One of these compounds is added for a second mechanism: more fat used for fuel, better energy, and in theory less of the slowdown in energy use that comes with losing weight. That logic is reasonable, but it has not been tested in a trial, so treat it as a theory being researched rather than a proven result.
What to know about side effects
Because human data is limited, the honest answer is that side effects are less well mapped than for the GLP-1s. AOD-9604 was well tolerated in its human studies. For the others, most of what is known comes from animal work, and injection-site redness is the most commonly reported issue with any injectable. None of these compounds should be combined with growth hormone or diabetes medication without understanding how they interact.
Frequently asked questions
Is AOD-9604 effective for fat loss?
It increased fat breakdown in animal studies, but a larger human trial did not show meaningful weight loss over placebo. It was well tolerated, which is why it is still researched, usually as a pairing alongside a GLP-1 rather than on its own.
Are 5-Amino-1MQ and SLU-PP-332 peptides?
No. Both are small molecules. They are sold alongside peptides because they are researched for the same goals: fat loss, energy and metabolic health.
Can these compounds replace semaglutide or tirzepatide?
Not on current evidence. The GLP-1 compounds have large human trials behind them. These four work on energy use rather than appetite and are mostly researched as additions to a GLP-1, not replacements.
What is the difference between MOTS-c and SLU-PP-332?
MOTS-c is a peptide your own mitochondria produce, which helps cells use glucose and fat. SLU-PP-332 is a synthetic small molecule that switches on endurance-related genes in muscle. They act on overlapping energy pathways from different starting points.
Sources
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology, 2001.
- Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 2018.
- Billon C et al. Synthetic ERR agonists and exercise capacity in mice. ACS Chemical Biology, 2023.
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
This article is for educational purposes only and is not medical advice. These compounds are sold for research use and none is a registered medicine in South Africa. Our guide to whether peptides are legal in South Africa explains what that means.
Everything we sell is supplied for research use only and is not a registered medicine. Nothing here is medical advice.
Related reading: fat burners vs peptides for weight loss and slimming injections in South Africa.
For the appetite side of the picture, see our GLP-1 guide. If you are researching NAD+ as well, NAD+ vs NMN covers the energy molecule that 5-Amino-1MQ is thought to protect.

